Expanded Access Treatment Protocol: Remdesivir for the Treatment of SARS-CoV2 (CoV) Infection
Due to the lack of proven treatment options for COVID-19, the only medical intervention currently available to patients who develop severe or life-threatening illness is supportive care. Developing and researching potential treatments in an expedited fashion is a priority in combating this disease. Remdesivir is an investigational medication that has been approved by the FDA for compassionate use in patients with COVID-19 who have developed severe or life-threatening illness. Remdesivir is an antiviral medication that is designed to prevent proliferation of the virus within the body. It has been tested in hundreds of patients with SARS-CoV-2, the virus that causes COVID-19, and preliminary results suggest that the medication may improve clinical outcomes and prevent further disease progression. This study is sponsored by Gilead Science, Inc.
Michael Bowie, email@example.com
A full description of this study can be found at https://www.clinicaltrials.gov using NCT04323761 as the identifier.
Overlake Medical Center
1035 116th Ave. NE
Bellevue, WA 98004